English
Nanocovax
Sign in to save~16 min read
Encyclopedic overview
13 sectionsContents
- Medical uses
- Clinical trials
- Preclinical and phase I
- Phase II
- Safety outcome
- Immunogenicity outcome
- Phase III
- Safety outcome
- Immunogenicity outcome
- Efficacy outcome
- Economics
- References
- External links
Nanocovax is a Vietnamese COVID-19 vaccine candidate developed by Nanogen Pharmaceutical Biotechnology JSC. It is a subunit vaccine (SARS‑CoV‑2 recombinant spike protein with aluminum adjuvant).
== Medical uses == The vaccine requires two doses, administered 28 days apart. It is given by intramuscular injection.
Excerpted from Wikipedia’s “Nanocovax” article, available under the CC BY-SA 4.0 licence.